Iron Isomaltoside 1000, ferric derisomaltose — Competitive Intelligence Brief

Iron Isomaltoside 1000, ferric derisomaltose (Iron Isomaltoside 1000, ferric derisomaltose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron replacement agent. Area: Hematology.

phase 3 Iron replacement agent Transferrin (iron transport protein) Hematology Small molecule

Target snapshot

Iron Isomaltoside 1000, ferric derisomaltose (Iron Isomaltoside 1000, ferric derisomaltose) — Saskatchewan Health Authority - Regina Area. Iron isomaltoside 1000 is an iron-carbohydrate complex that delivers ferric iron to bind transferrin and replenish iron stores in patients with iron deficiency.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Iron Isomaltoside 1000, ferric derisomaltose TARGET	Iron Isomaltoside 1000, ferric derisomaltose	Saskatchewan Health Authority - Regina Area	phase 3	Iron replacement agent	Transferrin (iron transport protein)
Triferic AVNU	Triferic AVNU	Rockwell Medical Technologies, Inc.	marketed	Iron replacement agent	Iron (Fe3+) delivery system
SFP	SFP	Rockwell Medical Technologies, Inc.	marketed	Intravenous iron replacement agent	Iron (Fe3+) for hemoglobin synthesis and erythropoiesis
Iron Carboxymaltose	Iron Carboxymaltose	Albina Nowak, MD	marketed	Intravenous iron replacement agent	Iron(III) ion; transferrin and ferritin (iron-binding proteins)
Generic sodium ferric gluconate	Generic sodium ferric gluconate	University of Maryland, Baltimore	marketed	Iron replacement agent	Iron (Fe3+) delivery; hemoglobin and myoglobin synthesis
High-dose ferric derisomaltose	High-dose ferric derisomaltose	China-Japan Friendship Hospital	marketed	Iron replacement agent
Ferric Carboxymaltose (FCM)	Ferric Carboxymaltose (FCM)	American Regent, Inc.	marketed	Intravenous iron replacement agent	Iron (Fe³⁺) delivery; transferrin and ferritin binding

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron replacement agent class)

1. University of Maryland, Baltimore · 2 drugs in this class
2. Ain Shams University · 1 drug in this class
3. American Regent, Inc. · 1 drug in this class
4. Azad Pharma AG · 1 drug in this class
5. CN NGANOU-GNINDJIO, MD, MSc · 1 drug in this class
6. China-Japan Friendship Hospital · 1 drug in this class
7. Hallym University Medical Center · 1 drug in this class
8. J. Uriach and Company · 1 drug in this class
9. JW Pharmaceutical · 1 drug in this class
10. Prince of Wales Hospital, Shatin, Hong Kong · 1 drug in this class